New Phase 3 trials registered, week of September 28, 2026: 9 industry trials

Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.

The trials

GlaxoSmithKline registers phase 3 trial of mRNA seasonal influenza vaccine. Sponsor: GlaxoSmithKline. Condition: Influenza, Human. Intervention: mRNA Seasonal Flu vaccine. Phase: Phase 3. Planned enrollment: 3,000. Planned primary completion: July 2027. First posted October 1, 2026. Record: NCT07851246.
Regeneron registers trial of ALN-CIDEB in Metabolic Dysfunction-Associated Steatotic Liver Disease. Sponsor: Regeneron Pharmaceuticals. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD. Intervention: ALN-CIDEB. Phase: Phase 3. Planned enrollment: 1,500. Planned primary completion: March 2029. First posted October 2, 2026. Record: NCT07854782.
Intra-Cellular Therapies registers JNJ-99245354 (ITI-1284) in generalized anxiety disorder. Sponsor: Intra-Cellular Therapies, Inc. Condition: Generalized Anxiety Disorder. Intervention: JNJ-99245354. Phase: Phase 3. Planned enrollment: 705. Planned primary completion: September 2030. First posted October 2, 2026. Record: NCT07856420.
Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD. Sponsor: Boehringer Ingelheim. Conditions: Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease. Intervention: Survodutide. Phase: Phase 3. Planned enrollment: 600. Planned primary completion: April 2029. First posted September 30, 2026. Record: NCT07850063.
Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis. Sponsor: Jiankuan (Suzhou) Biotechnology Company Limited. Condition: Rheumatoid Arthrits. Intervention: Proximod. Phase: Phase 3. Planned enrollment: 590. Planned primary completion: April 2027. First posted October 2, 2026. Record: NCT07856511.
Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes. Sponsor: Boehringer Ingelheim. Condition: Obesity. Intervention: Survodutide. Phase: Phase 3. Planned enrollment: 350. Planned primary completion: June 2028. First posted October 2, 2026. Record: NCT07855900.
Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy. Sponsor: Novartis Pharmaceuticals. Condition: IgA Nephropathy (IgAN). Interventions: zigakibart, atrasentan. Phase: Phase 3. Planned enrollment: 340. Planned primary completion: September 2028. First posted September 30, 2026. Record: NCT07850752 (LUMINA IgAN).
PT Bio Farma registers Phase 3 trial of in-house recombinant Hepatitis B vaccine at birth dose. Sponsor: PT Bio Farma. Conditions: Vaccination Adverse Event, Immunogenicity, Vaccine. Interventions: In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine. Phase: Phase 3. Planned enrollment: 270. Planned primary completion: February 2027. First posted October 2, 2026. Record: NCT07854847.
Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy. Sponsor: Amgen. Condition: Glomerulonephritis, Membranous. Interventions: Inebilizumab, Tacrolimus. Phase: Phase 3. Planned enrollment: 159. Planned primary completion: September 2031. First posted October 1, 2026. Record: NCT07851220 (MOMENT).

By the numbers

Trials: 9, from 8 lead sponsors.
Planned enrollment: 7,514 in all across 9 trials; median 590 per trial.
Largest: GlaxoSmithKline's mRNA Seasonal Flu vaccine trial, 3,000. Smallest: Amgen's MOMENT trial, 159.
Sponsors with more than one trial: Boehringer Ingelheim (2).
Phases as registered: 9 Phase 3.
Planned primary completion: from February 2027 to September 2031.

How this page is made

Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.